ASCO Data Shows New Therapy Delays Breast Cancer Progression and May Improve Quality of Life for Women with Hormone ...

Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving ...

A recent study reveals rising early-onset colorectal cancer rates, highlighting disparities and the need for improved ...

New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, “significantly reduced” breast tissue cell growth, which is a major indicator of cancer ...

Karen Eubanks Jackson has reshaped the conversation around breast cancer for Black women in America—and now, with the ASCO ...

The study adds to growing evidence that digital tools can maximize genetic counselors' limited time without patient harm.

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50.

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

Multiple myeloma is considered incurable, but a third of patients in a clinical trial have lived without detectable cancer for years, after facing certain death ...

On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a ...